Evidence map›Paper›PMID 40668404›Full record

Observational studyNeuroradiology2025

Dose-response and infusion duration of intra-arterial nimodipine in cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a single-center case series.

Adrien Guenego, Hamza Adel Salim, Fabio Silvio Taccone, Jeremy J Heit, Maud Wang, Niloufar Sadeghi, Noémie Ligot, Valentina Lolli, Vivek Yedavalli, Max Wintermark and 2 more

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05276934 (Prospective Assessment of Brain Imaging After Aneurysmal of AVM-related Intracranial Hemorrhage), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05276934 unknown statusnot on this map

Prospective Assessment of Brain Imaging After Aneurysmal of AVM-related Intracranial Hemorrhage

TypeobservationalSponsorErasme University HospitalRan2022 to 2025Enrolled100ConditionsAneurysm, Ruptured, Aneurysmal Subarachnoid Hemorrhage, Arteriovenous Malformations, Intracranial AneurysmArmsBrain computed tomography
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adrien GuenegoErasme University Hospital, Brussels, Belgium. adrienguenego@gmail.com.
Hamza Adel SalimMD Anderson Medical Center, Houston, TX, USA. Hamza.sleeem@gmail.com.
Fabio Silvio TacconeHôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.
Jeremy J HeitStanford Medical Center, Palo Alto, CA, USA.
Maud WangHôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.
Niloufar SadeghiHôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.
Noémie LigotHôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.
Valentina LolliHôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.
Vivek YedavalliJohns Hopkins Medical Center, Baltimore, MD, USA.
Max WintermarkMD Anderson Medical Center, Houston, TX, USA.
Fadi TannouriHôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.
Boris LubiczErasme University Hospital, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis single-center case series evaluates the effects on arterial diameter, perfusion imaging, and safety of intra-arterial (IA) nimodipine administration for CV following aSAH.

methodsIn this prospective single-center observational study (SAVEBRAIN PWI; NCT05276934), 14 patients with CV refractory to medical treatment were treated with IA nimodipine. We assessed changes in vessel diameter and perfusion parameters pre- and post-treatment. Associations between nimodipine dose, infusion duration, and outcomes were analyzed using regression models.

resultsThe median age of patients was 48 years; 50% were male. The median nimodipine dose was 2.00 mg with a median infusion duration of 10 minutes. Post-treatment, the median artery diameter increased from 1.50 mm to 1.90 mm (25% change), TMAX decreased from 2.58 to 2.11 seconds, and TTD decreased from 4.58 to 4.09 seconds. Higher nimodipine doses (> 2 mg) were associated with increased odds of hypotension requiring injection breaks (OR 3.6, 95% CI 2.1 to 5.6, p < 0.001). Retreatment was necessary in 69% of cases, with a median time to retreatment of 2 days.

conclusionsIA nimodipine administration appears to improve vascular diameters and perfusion parameters in CV following aSAH but carries a significant risk of hypotension, especially at doses > 2 mg. Longer infusion durations may reduce hypotension risk. These findings emphasize the need for careful dose management and further research to standardize treatment protocols.

Indexed as

NimodipineSubarachnoid HemorrhageVasodilator AgentsVasospasm, IntracranialAdultCerebral AngiographyDose-Response Relationship, DrugFemaleHumansInfusions, Intra-ArterialMaleMiddle AgedProspective StudiesTreatment OutcomeNimodipineVasodilator AgentsAneurysmal subarachnoid hemorrhageCerebral vasospasmChemical angioplastyDelayed cerebral ischemiaIntra-arterial nimodipine

Identifiers

PMID40668404

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.